EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The KRAS signaling pathway's impact on the characteristics of pancreatic cancer cells

ZhangXing Chen, Meiyan Chen, Yuka Fu, Jingyi Zhang

Pathology - Research and Practice · 2023

DOI: 10.1016/j.prp.2023.154603 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pathology - Research and Practice, 2023. Verfasst von ZhangXing Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Success Hospital Affiliated to Xiamen University, Xiamen, Fujian 361000, China. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 57 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is classified as a cancer with high metastasis so that its mortality rate is high and most of the patients could not survive longer than 5 years. RAS signaling participate in cellular processes, so it has a key role in PDAC.RAS activation is associated via three different signaling pathway including somatic oncogenic point mutations in KRAS, upstream signaling like EGFR, oncogenic activation of the downstream B-RAF molecule. Several targeted therapies have been developed against kinase effectors particularly those in the MAPK and PI3K (phosphoinositide 3-kinase)/mTOR signaling pathways and several inhibitors are undergoing clinical studies at the moment. However, because it is highly metastatic and frequently diagnosed at advanced disease stages, pancreatic cancer continues to be a challenging cancer to treat. This article will explore therapeutic approaches that focus on oncogenic KRAS signaling in pancreatic cancer and provide an updated synopsis of our knowledge of how mutant KRAS function in the illness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalHumansProto-Oncogene Proteins p21(ras)Phosphatidylinositol 3-KinasesSignal TransductionMutation

Stichwörter der Autor:innen

KRASPancreatic cancerSignalingTherapy

Substanzen

Proto-Oncogene Proteins p21(ras)Phosphatidylinositol 3-KinasesKRAS protein, human

Autor:innen und Institutionen

  • Department of Gastroenterology, Success Hospital Affiliated to Xiamen University, Xiamen, Fujian 361000, China.
  • Department of Gastroenterology, Success Hospital Affiliated to Xiamen University, Xiamen, Fujian 361000, China. Electronic address: cmy2662@163.com.

Zitieren

APA

Chen, Z., Chen, M., Fu, Y., & Zhang, J. (2023). The KRAS signaling pathway's impact on the characteristics of pancreatic cancer cells. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2023.154603

Vancouver

Chen Z, Chen M, Fu Y, Zhang J. The KRAS signaling pathway's impact on the characteristics of pancreatic cancer cells. Pathology - Research and Practice. 2023. doi:10.1016/j.prp.2023.154603

BibTeX
@article{Chen2023,
  author = {Chen, ZhangXing and Chen, Meiyan and Fu, Yuka and Zhang, Jingyi},
  title = {The KRAS signaling pathway's impact on the characteristics of pancreatic cancer cells},
  journal = {Pathology - Research and Practice},
  year = {2023},
  doi = {10.1016/j.prp.2023.154603}
}
Kostenlos starten →